NO155239C - Analogifremgangsmaate ved fremstilling av terapeutisk aktive, blandede salter av essensielle eller semi-essensielle aminosyrer og nitrogenfri analoger derav. - Google Patents

Analogifremgangsmaate ved fremstilling av terapeutisk aktive, blandede salter av essensielle eller semi-essensielle aminosyrer og nitrogenfri analoger derav.

Info

Publication number
NO155239C
NO155239C NO801119A NO801119A NO155239C NO 155239 C NO155239 C NO 155239C NO 801119 A NO801119 A NO 801119A NO 801119 A NO801119 A NO 801119A NO 155239 C NO155239 C NO 155239C
Authority
NO
Norway
Prior art keywords
essential
semi
preparation
amino acids
mixed salts
Prior art date
Application number
NO801119A
Other languages
English (en)
Other versions
NO801119L (no
NO155239B (no
Inventor
Mackenzie Walser
Original Assignee
Univ Johns Hopkins
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Johns Hopkins filed Critical Univ Johns Hopkins
Publication of NO801119L publication Critical patent/NO801119L/no
Publication of NO155239B publication Critical patent/NO155239B/no
Publication of NO155239C publication Critical patent/NO155239C/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/64—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms, e.g. histidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C07D209/18—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D209/20—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals substituted additionally by nitrogen atoms, e.g. tryptophane

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Urology & Nephrology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Diabetes (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
NO801119A 1979-04-18 1980-04-17 Analogifremgangsmaate ved fremstilling av terapeutisk aktive, blandede salter av essensielle eller semi-essensielle aminosyrer og nitrogenfri analoger derav. NO155239C (no)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US06/031,274 US4296127A (en) 1979-04-18 1979-04-18 Mixed salts of essential or semi-essential amino acids and nitrogen-free analogs thereof

Publications (3)

Publication Number Publication Date
NO801119L NO801119L (no) 1980-10-20
NO155239B NO155239B (no) 1986-11-24
NO155239C true NO155239C (no) 1987-03-04

Family

ID=21858554

Family Applications (1)

Application Number Title Priority Date Filing Date
NO801119A NO155239C (no) 1979-04-18 1980-04-17 Analogifremgangsmaate ved fremstilling av terapeutisk aktive, blandede salter av essensielle eller semi-essensielle aminosyrer og nitrogenfri analoger derav.

Country Status (16)

Country Link
US (1) US4296127A (no)
JP (1) JPS6024094B2 (no)
BE (1) BE882833A (no)
CA (1) CA1139768A (no)
DE (1) DE3015076A1 (no)
DK (1) DK159147C (no)
ES (1) ES490649A0 (no)
FI (1) FI70206C (no)
FR (1) FR2454434A1 (no)
GB (1) GB2048867B (no)
IE (1) IE49586B1 (no)
IT (1) IT1141482B (no)
LU (1) LU82369A1 (no)
NL (1) NL191583C (no)
NO (1) NO155239C (no)
SE (1) SE460902B (no)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1985003002A1 (en) * 1984-01-16 1985-07-18 Baxter Travenol Laboratories, Inc. Parenteral nutrition with medium and long chain triglycerides
DE3438455A1 (de) * 1984-10-19 1986-06-26 Institut Dr. Ziegler, Bettingen L-lysin- und l-histidinpyruvat
US4677121A (en) * 1985-01-22 1987-06-30 The Johns Hopkins University Method of inhibiting muscle protein degradation
US4752619A (en) * 1985-12-23 1988-06-21 The Johns Hopkins University Nutritional supplement for treatment of uremia
US4744990A (en) * 1986-09-25 1988-05-17 W. R. Grace & Co. Hydantoins as animal food supplements
US4871552A (en) * 1986-09-25 1989-10-03 W. R. Grace & Co.-Conn. Hydantoins as animal food supplements
FR2615734B1 (fr) * 1987-05-27 1989-12-01 Synthelabo Compositions pharmaceutiques contenant un melange de sels de cetoacides et d'amino-acides utiles pour le traitement de l'uremie
FR2618331B1 (fr) * 1987-07-23 1991-10-04 Synthelabo Compositions pharmaceutiques utiles pour le traitement de l'uremie
JP2522034B2 (ja) * 1988-12-27 1996-08-07 味の素株式会社 α−ケト酸・アミノ酸塩化合物及びその製造方法
US4957938A (en) * 1989-06-21 1990-09-18 Abbott Laboratories Nutritional formulation for the treatment of renal disease
DE3936319C3 (de) * 1989-11-01 1997-05-07 Bartz Volker Phosphatbinder zur oralen Verabreichung
DE3940052A1 (de) * 1989-12-04 1991-06-06 Nephro Medica Pharma Dialysier- und spuelloesung zur intraperitonealen verabreichung
DE3943424A1 (de) * 1989-12-30 1991-07-04 Nephro Medica Pharma Infusions- und injektionsloesung zur intravenoesen verabreichung
US5234696A (en) * 1991-12-27 1993-08-10 Abbott Laboratories Method of producing tablets, tablets produced thereby, and method of treatment using same
US5256697A (en) * 1992-04-16 1993-10-26 Abbott Laboratories Method of administering pyruvate and methods of synthesizing pyruvate precursors
US5276018A (en) * 1992-07-17 1994-01-04 Brigham And Women's Hospital Composition comprising amino acids and methods for decreasing muscle breakdown
US6797289B2 (en) * 1998-02-13 2004-09-28 Nutramax Laboratories, Inc. Use of anabolic agents, anti-catabolic agents, antioxidant agents, and analgesics for protection, treatment and repair of connective tissues in humans and animals
US20070141181A1 (en) 1998-02-13 2007-06-21 Nutramax Laboratories, Inc. Use of anabolic agents, anti-catabolic agents, antioxidant agents, and analgesics for protection, treatment and repair of connective tissues in humans and animals
US20010000472A1 (en) * 1998-02-27 2001-04-26 Nutramax Laboratories, Inc. L-ergothioneine, milk thistle, and s-adenosylmethionine for the prevention, treatment and repair of liver damage
CA2321565C (en) 1998-02-27 2014-10-14 Nutramax Laboratories, Inc. L-ergothioneine, milk thistle, and s-adenosylmethionine for the prevention, treatment and repair of liver damage
US8680329B2 (en) * 2010-10-13 2014-03-25 Tianjin Tiancheng Pharmaceutical Co., Ltd. (China) Process for preparation of α-ketoglutaric acid
US8754256B2 (en) * 2010-10-13 2014-06-17 Tianjin Tiancheng Pharmaceutical Co., Ltd. (China) Process for preparation of L-Arginine α-ketoglutarate 1:1 and 2:1
US20140187815A1 (en) * 2012-12-28 2014-07-03 Guoji Zhang Process for preparation of l-arginine alpha-ketoglutarate 1:1 and 2:1
US20220204918A1 (en) * 2019-04-11 2022-06-30 Merck Patent Gmbh Cell culture media comprising keto acids

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2457820A (en) * 1945-12-27 1949-01-04 Merck & Co Inc Amino acid solution and process for preparing the same
US3441650A (en) * 1965-07-23 1969-04-29 Lab Jacques Logeais Sa Therapy of ammonical intoxications by di-l-ornithine alpha-ketoglutarate
US3764703A (en) * 1969-11-07 1973-10-09 Astra Ab Amino acid mixture for use in treatment of uremic conditions
DE2335215B2 (de) * 1972-07-13 1979-04-05 The Johns Hopkins University, Baltimore, Md. (V.St.A.) Verwendung einer Mischung bei der Bekämpfung von zur Urämie führenden Nierenerkrankungen
GB1442154A (en) * 1973-04-30 1976-07-07 Walser M Composition for promotion of protein synthesis and suppression of urea formation in the body
GB1511302A (en) * 1974-04-15 1978-05-17 Univ Johns Hopkins Pharmaceutical compositions comprising amino acid analogues
US4100293A (en) * 1974-04-15 1978-07-11 The Johns Hopkins University Treatment of hepatic disorders with therapeutic compositions comprising keto analogs of essential amino acids
FR2315916A2 (fr) * 1976-03-23 1977-01-28 Univ Johns Hopkins Melanges therapeutiques comprenant des analogues alpha hydroxy acides d'acides amines essentiels et leur administration a l'homme en vue de l'amelioration de la synthese proteique et la suppression de la formation d'uree
DE2759133A1 (de) * 1976-12-31 1978-07-13 Carmelo Prof Giordano Gemisch essentieller aminosaeuren und/oder analoger ketosaeuren und verwendung derselben diaetzusatz bei niereninsuffizienz
US4228099A (en) * 1978-03-17 1980-10-14 The Johns Hopkins University Ornithine and arginine salts of branched chain keto acids and uses in treatment of hepatic and renal disorders

Also Published As

Publication number Publication date
IT8021498A0 (it) 1980-04-18
CA1139768A (en) 1983-01-18
DK159147B (da) 1990-09-10
US4296127A (en) 1981-10-20
JPS6024094B2 (ja) 1985-06-11
DE3015076C2 (no) 1988-01-21
IT1141482B (it) 1986-10-01
FI70206C (fi) 1986-09-15
IE49586B1 (en) 1985-10-30
SE8002900L (sv) 1980-12-12
ES8102804A1 (es) 1981-02-16
NL8002297A (nl) 1980-10-21
ES490649A0 (es) 1981-02-16
DK159147C (da) 1991-02-11
NO801119L (no) 1980-10-20
IE800781L (en) 1980-10-19
FR2454434B1 (no) 1984-02-24
FI70206B (fi) 1986-02-28
BE882833A (fr) 1980-08-18
NO155239B (no) 1986-11-24
NL191583B (nl) 1995-06-01
FI801225A (fi) 1980-10-19
LU82369A1 (fr) 1980-07-31
DE3015076A1 (de) 1980-10-30
SE460902B (sv) 1989-12-04
GB2048867A (en) 1980-12-17
NL191583C (nl) 1995-10-03
JPS5653641A (en) 1981-05-13
FR2454434A1 (fr) 1980-11-14
GB2048867B (en) 1983-03-16
DK163180A (da) 1980-10-19

Similar Documents

Publication Publication Date Title
NO155239C (no) Analogifremgangsmaate ved fremstilling av terapeutisk aktive, blandede salter av essensielle eller semi-essensielle aminosyrer og nitrogenfri analoger derav.
NO882732L (no) Fremgangsmaate for fremstilling av terapeutisk aktive aminosyrederivater.
NO851949L (no) Analogifremgangsmaate for fremstilling av terapeutisk aktive aminotetralinderivater.
NO803259L (no) Analogifremgangsmaate for fremstilling av terapeutisk aktive trans-4-fenyl-1,2,3,4-tetrahydro-1-naftalenaminderivater
SE8504720L (sv) Ny lekemedelsberedning
NO880182L (no) Fremgangsmaate for fremstilling av terapeutisk aktive 1,2-dihydro-3h-indazol-3-on-derivater.
NO165148C (no) Analogifremgangsmaate for fremstilling av terapeutisk aktive derivater av tricykliske aminosyrer.
NO871295D0 (no) Fremgangsmaate for fremstilling av terapeutisk aktive aminosyrederivater.
NO166080C (no) Analogifremgangsmaate for fremstilling av terapeutisk aktive 5,6,8-trifluorkinoliner.
NO863671L (no) Fremgangsmaate for fremstilling av terapeutisk aktive tetrahydro-2-heterocykloalkylpyrido(4,3)indoler.
NO870049L (no) Analogifremgangsmaate for fremstilling av terapeutisk aktive aminosyrederivater.
NO883122D0 (no) Fremgangsmaate for fremstilling av terapeutisk aktive arylamid-derivater.
NO165071C (no) Analogifremgangsmaate for fremstilling av terapeutisk aktive 7-(3-amino-1-pyrrolidinyl)-8-klor-1-cyklopropyl-6- fluor-1,4,-dihydro-4-okso-3-kinolin-karboksylsyre.
NO863373L (no) Analogifremgangsmaate for fremstilling av terapeutisk aktive aminosyrederivater.
NO155289C (no) Analogifremgangsmaate for fremstilling av terapeutisk virksomme 4,5-umettede prostansyrederivater.
NO165104C (no) Analogifremgangsmaate til fremstilling av terapeutisk aktive 1, 1-disubstituerte cyklopropanderivater.
NO147876C (no) Analogifremgangsmaate til fremstilling av terapeutisk virksomme 2,2`-ditio-bis-(benzamid)-derivater eller salter derav
NO891114L (no) Analogifremgangsmaate for fremstilling av terapeutisk aktive arakidonsyre-derivater.
NO172495C (no) Fremgangsmaate for fremstilling av terapeutisk aktive, ikke-mettede aminosyreforbindelser
NO165542C (no) Analogifremgangsmaate for fremstilling av terapeutisk aktive 5-aryl-2,4-dialkyl-3h-1,2,4-triazol-3-thioner.
NO162468C (no) Analogifremgangsmaate for fremstilling av terapeutisk aktive 12-amino-pyridazino (4[,5[;3,4)-pyrrolo-( 2,1-a)-isokinolinderivater.
NO913644D0 (no) Fremgangsmaate for fremstilling av terapeutisk aktive aminosyrederivater.
NO165999C (no) Analogifremgangsmaate til fremstilling av terapeutisk aktive n-(2-aminoetyl)benzamid-derivater.
NO171499C (no) Analogifremgangsmaate for fremstilling av terapeutisk aktive 5,6-dihydro-4h-cyklo-penta(b)tiofen-6-karboksylsyre-derivater
NO164533C (no) Analogifremgangsmaate ved fremstilling av terapeutisk aktive cyclohexansyrer.